Yahoo · Sep 1, 2026
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GAITHERSBURG, Md., September 01, 2026--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity
WG
NASDAQ · WGS
GeneDx Holdings Corp.
Healthcare · Medical - Healthcare Information Services
$83.96
Up+$1.67 (+1.99%)
Updated Sep 11, 2026, 2:49 PM
SID Score
5.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.49B
- P/E ratio
- 2,147.87
- Dividend yield
- 0.00%
- 52-week range
- $32.21 – $95.38
- Volume
- 711.68K
- Avg. volume
- 519.06K
Price performance
WGS price history
1M range · 20 trading sessions · Daily adjusted prices
WGS closed at $83.96 after 20 trading sessions, up 6.08% for the selected period.
- Last close
- $83.96
- Period change
- +6.08%
- Period low
- $76.34
- Period high
- $90.29
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $83.85 | $87.1346 | $82.00 | $83.96 | 711.68K |
| Sep 9, 2026 | $84.22 | $88.84 | $84.00 | $86.48 | 493.1K |
| Sep 8, 2026 | $85.31 | $86.57 | $83.00 | $85.87 | 426.65K |
| Sep 4, 2026 | $87.78 | $87.99 | $84.1601 | $85.99 | 304.44K |
| Sep 3, 2026 | $88.38 | $90.00 | $85.35 | $87.39 | 484.25K |
| Sep 2, 2026 | $83.94 | $87.2788 | $83.70 | $86.72 | 500.13K |
| Sep 1, 2026 | $83.84 | $85.75 | $82.79 | $84.81 | 342.09K |
| Aug 31, 2026 | $84.79 | $85.305 | $81.1901 | $84.81 | 504.19K |
| Aug 28, 2026 | $88.79 | $89.74 | $85.925 | $86.335 | 435.34K |
| Aug 27, 2026 | $90.32 | $91.78 | $88.55 | $89.24 | 354.34K |
| Aug 26, 2026 | $85.98 | $90.54 | $84.9083 | $90.285 | 430.35K |
| Aug 25, 2026 | $85.50 | $88.21 | $83.8775 | $87.405 | 682.92K |
| Aug 24, 2026 | $86.31 | $86.40 | $84.1657 | $85.19 | 504.42K |
| Aug 21, 2026 | $83.71 | $87.17 | $80.76 | $87.065 | 555.28K |
| Aug 20, 2026 | $79.295 | $84.41 | $78.80 | $82.55 | 453.35K |
| Aug 19, 2026 | $78.31 | $81.28 | $77.90 | $79.65 | 672.86K |
| Aug 18, 2026 | $76.39 | $78.60 | $75.15 | $76.34 | 389.52K |
| Aug 17, 2026 | $77.39 | $79.82 | $77.05 | $77.39 | 431.95K |
| Aug 14, 2026 | $78.68 | $79.3699 | $76.9787 | $78.08 | 391.86K |
| Aug 13, 2026 | $82.58 | $83.11 | $77.79 | $79.15 | 715.12K |
Latest WGS news
The latest Smart Investors Daily articles mentioning WGS.
Stock researchCompany · Overview
WGS research
Overview
Company profile and research snapshot.
Company profile
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $153.75
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Canaccord Genuity | Buy | — |
| Aug 4, 2026 | BTIG | Buy | — |
| Jun 29, 2026 | Guggenheim | Buy | — |
| Jun 23, 2026 | Piper Sandler | Overweight | — |
| May 5, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 24, 2026
Top Stock Picks for Week of August 24, 2026
A Semiconductor Packaging Company with Strong Financial Momentum and a Medical Services Company with Solid Short-Term Price Momentum.
Yahoo · Aug 24, 2026
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
GAITHERSBURG, Md., August 24, 2026--GeneDx and Seattle Children’s show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
Benzinga · Aug 24, 2026
GeneDx Announces New Data Published In Genetics In Medicine Demonstrating First‑Tier Rapid Genome Sequencing Improves Diagnostic Rates, Patient Outcomes, And Operational Efficiency In Pediatric Care
Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosisChildren experiencing faltering growth saw
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
